Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Franco-Nevada Corporation (FNV) vs Stryker Corporation (SYK) Price & Performance

Franco-Nevada CorporationTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

Franco-Nevada Corporation vs Stryker Corporation — how do they compare? Franco-Nevada Corporation trades at $238.3 (market cap $45.36B), while Stryker Corporation trades at $285.51 (market cap $108.02B). The key difference: Stryker Corporation is far larger — about 2.4× Franco-Nevada Corporation's market cap, and Stryker Corporation pays the higher dividend (1.25%). Which is the better fit depends on your goals — on Pluang, investors hold Franco-Nevada Corporation for 0 Days and Stryker Corporation for 22 Days on average.

FNVSYK
Market Cap
$45.36B$108.02B
Volume
787,8412,222,698
Sector
Basic MaterialsHealth
52-Week High
$280.82$388.35
52-Week Low
$183.97$269.75
Typical Hold Time
0 Days22 Days
Enterprise Value
$44.34B$119.49B
Dividend Yield
0.75%1.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Franco-Nevada Corporation

Franco-Nevada (FNV) trades at $243.85, showing a slight decline of 0.77% over the past day. The stock is positioned neutrally from a technical perspective, with key support near $242 and resistance at $246. Fundamentally, the company exhibits strong profitability with a net income margin of 63.79% and has beaten earnings expectations in two of the last three quarters. Recent news highlights portfolio expansion, including a significant investment in the Bullabulling Gold Project and positive developments regarding the potential restart of the Cobre Panama mine.

The outlook for FNV is supported by analyst consensus, with a price target of $275 suggesting potential upside. Key opportunities include revenue growth from new projects and high profit margins. Risks involve execution on new investments, commodity price volatility, and geopolitical factors affecting mining operations. The balanced analyst rating split indicates cautious optimism for future performance.

Stryker Corporation

Stryker (SYK) trades at $282.63, showing minimal daily change. The stock exhibits neutral technical signals with mixed moving averages and oscillators. Fundamentally, the company maintains strong profitability with a 14.43% net income margin and 16.51% ROE. Recent Q2 2026 earnings beat expectations, though Q1 2026 was a miss. Analyst sentiment is strongly bullish with a $365.89 consensus price target, but recent news highlights legal investigations and a manufacturing issue disclosure that caused an 8.8% share drop in early September 2026.

The outlook for SYK is cautiously optimistic. Strong fundamentals and analyst support suggest upside potential, but near-term risks from legal scrutiny and operational challenges could pressure the stock. Investors should weigh robust financial health against headline volatility ahead of Q3 2026 earnings on October 29, 2026.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FNV
100% Buy0% Sell
Avg holding period · 0 Days
SYK
100% Buy0% Sell
Avg holding period · 22 Days

Top news

Latest headlines on both assets

About Franco-Nevada Corporation

Franco-Nevada Corporation is a royalty and streaming company that finances mining and energy projects in exchange for royalty payments or the right to purchase output at set prices, holding a diversified portfolio across Precious Metals, Other Mining, and Energy (oil, gas, and natural gas liquids).

Read more on FNV →

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK →